✦ LIBER ✦

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

✍ Scribed by Esther N. Oliva; Maria Cuzzola; Francesco Nobile; Francesca Ronco; Maria Grazia D’Errigo; Carmelo Laganà; Fortunato Morabito; Sara Galimberti; Agostino Cortelezzi; Maria A. Aloe Spiriti; Giorgina Specchia; Antonella Poloni; Massimo Breccia; Riccardo Ghio; Carlo Finelli; Pasquale Iacopino; Giuliana Alimena; Roberto Latagliata

Book ID: 114794798
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 80 KB
Volume: 85
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2010.01473.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Lenalidomide is active in Japanese patie

Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality

✍ Hironori Harada; Mitsumasa Watanabe; Kenshi Suzuki; Soshi Yanagita; Takahiro Suz 📂 Article 📅 2009 🏛 Carden Jennings Publishing 🌐 English ⚖ 228 KB

Lenalidomide: A Review of its Use in Pat

Lenalidomide: A Review of its Use in Patients with Transfusion-Dependent Anaemia due to Low- or Intermediate-1-Risk Myelodysplastic Syndrome Associated with 5q Chromosome Deletion

✍ Syed, Yahiya Y.; Scott, Lesley J. 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 486 KB

Phase 1 dose-ranging study of ezatiostat

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)

✍ Azra Raza, Naomi Galili, Deborah Mulford, Scott E Smith, Gail L Brown, David P S 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 203 KB

Health-related quality of life outcomes

✍ Revicki, Dennis A.; Brandenburg, Nancy A.; Muus, Petra; Yu, Ren; Knight, Robert; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 321 KB

Lenalidomide in International Prognostic

Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy

✍ Oliva, Esther N.; Latagliata, Roberto; Laganà, Carmelo; Breccia, Massimo; Galimb 📂 Article 📅 2013 🏛 Informa plc 🌐 English ⚖ 564 KB